Eli Lilly signed a discovery-stage collaboration with Beijing-based InnoCare Pharma, reported as worth up to $3.35 billion, to identify and advance compounds across as many as five undisclosed targets. The deal adds another China-focused partnership to Lilly’s recent licensing and R&D expansion strategy. Under the arrangement, InnoCare will deploy its drug-discovery platform to generate candidates, while Lilly secures rights to further develop and commercialize outcomes. Reported economics include up-front and near-term payments of up to $100 million, plus development and milestone payments that can reach $3.25 billion, along with royalties. For investors and operators, the headline is that Lilly is actively sourcing early-stage innovation from China while keeping downstream control for later development and commercialization. That approach mirrors how larger companies are managing portfolio risk across modality and target selection. The agreement’s target count suggests breadth rather than single-asset focus, which can accelerate selection of lead programs if platform outputs prove strong.